Oncotarget

Research Papers:

KDM5A and PHF2 positively control expression of pro-metastatic genes repressed by EWS/Fli1, and promote growth and metastatic properties in Ewing sarcoma

Tyler S. McCann, Janet K. Parrish, Joseph Hsieh, Marybeth Sechler, Lays M. Sobral, Chelsea Self, Kenneth L. Jones, Andrew Goodspeed, James C. Costello and Paul Jedlicka _

PDF  |  Full Text  |  Supplementary Files  |  How to cite  |  Press Release

Oncotarget. 2020; 11:3818-3831. https://doi.org/10.18632/oncotarget.27737

Metrics: PDF 1495 views  |   Full Text 3431 views  |   ?  


Abstract

Tyler S. McCann1, Janet K. Parrish1, Joseph Hsieh1,2,3, Marybeth Sechler1,3, Lays M. Sobral1, Chelsea Self4, Kenneth L. Jones4,6, Andrew Goodspeed5,6, James C. Costello5,6 and Paul Jedlicka1,2,3

1 Department of Pathology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA

2 Medical Scientist Training Program, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA

3 Cancer Biology Graduate Program, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA

4 Department of Pediatrics, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA

5 Department of Pharmacology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA

6 Bioinformatics Shared Resource, University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, CO, USA

Correspondence to:

Paul Jedlicka,email: [email protected]

Keywords: Ewing sarcoma; metastasis; epigenetics; Jumonji-domain histone demethylase

Received: July 22, 2020     Accepted: August 24, 2020     Published: October 27, 2020

Copyright: © 2020 McCann et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Ewing sarcoma is an aggressive malignant neoplasm with high propensity for metastasis and poor clinical outcomes. The EWS/Fli1 oncofusion is the disease driver in > 90% of cases, but presents a difficult therapeutic target. Moreover, EWS/Fli1 plays a complex role in disease progression, with inhibitory effects on critical steps of metastasis. Like many other pediatric cancers, Ewing sarcoma is a disease marked by epigenetic dysregulation. Epigenetic mechanisms present alternative targeting opportunities, but their contributions to Ewing sarcoma metastasis and disease progression remain poorly understood. Here, we show that the epigenetic regulators KDM5A and PHF2 promote growth and metastatic properties in Ewing sarcoma, and, strikingly, activate expression many pro-metastatic genes repressed by EWS/Fli1. These genes include L1CAM, which is associated with adverse outcomes in Ewing sarcoma, and promotes migratory and invasive properties. KDM5A and PHF2 retain their growth promoting effects in more metastatically potent EWS/Fli1low cells, and PHF2 promotes both invasion and L1CAM expression in this cell population. Furthermore, KDM5A and PHF2 each contribute to the increased metastatic potency of EWS/Fli1low cells in vivo. Together, these studies identify KDM5A and PHF2 as novel disease-promoting factors, and potential new targets, in Ewing sarcoma, including the more metastatically potent EWS/Fli1low cell population.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27737